BMI View: While the Turkish pharmaceutical industry has achieved some concessions following additional price cuts and public discounts announced in November 2011, the impact of the November decree remains negative. That aside, BMI emphasises that the number-one concern for drugmakers in 2012 ...

more

BMI View: On account of its unpredictable and unfavourable operating environment and limited funding for and investment in healthcare and medicines, Zimbabwe’s pharmaceutical market will remain unattractive to foreign companies for the foreseeable future. Poor healthcare provision and ...

more

BMI View: It is vital the Tanzanian government assesses its medicine procurement systems. The expiry of medicines does not bode well for the state and its high reliance on donor funding for the healthcare sector, particularly as reports have highlighted the poor availability of essential ...

more

BMI View: We retain our negative outlook for the pharmaceutical market in the Czech Republic, expecting a 1.8% contraction in its value in local currency terms in 2012, following the 1.0% year-onyear (y-o-y) decrease calculated for 2011. While the increase in the value-added tax (VAT) will ...

more

BMI View: Uganda's pharmaceutical market is typical of developing markets: defined by an absence of a clear regulatory framework, a dependence upon drug imports and low healthcare expenditure per capita. Economic growth will aid the development of Uganda's pharmaceutical and healthcare ...

more

BMI View: Venezuela’s pharmaceutical industry will face increasingly harsh pricing policy which is unlikely to tackle the persistent medicine shortage problem. President Hugo Chávez's renewed attempts to regulate the country's pharmaceutical sector has prevented meaningful domestic and ...

more

BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for ...

more

BMI View: Despite concerted progress made on the fiscal consolidation front in the first half of 2011, the French government’s medium-term fiscal targets remain on the optimistic side, particularly given the deteriorating global macroeconomic backdrop and the potential need for state-led ...

more

BMI View: Puerto Rico is struggling to retain its reputation as a pharmaceutical manufacturing hub, with a number of plants found to be in breach of regulations and standards over recent years. Additionally, the flagging economy is expected to push skilled staff to emigrate, leaving fewer ...

more

BMI View: Thailand is a moderately attractive pharmaceutical market for multinationals. On the positive side, rewards are potentially considerable, given the country’s epidemiological profile and the growing population numbers. However, the government’s stance on compulsory licences and ...

more